Can norepinephrine (Levophed) be initiated in a patient with hypotension and gangrene?

Yes, you can start norepinephrine in a patient with hypotension and gangrene, but the presence of pre-existing gangrene requires careful risk-benefit assessment and heightened vigilance.

Primary Recommendation

Norepinephrine remains the first-choice vasopressor for hypotension even in patients with gangrene, as restoring adequate perfusion pressure is life-saving and takes priority over limb-threatening concerns 1. The Surviving Sepsis Campaign guidelines strongly recommend norepinephrine as first-line vasopressor therapy (strong recommendation, moderate quality evidence) 1.

Critical Context from FDA Labeling

The FDA label for Levophed provides important contraindications and warnings 2:

• Relative contraindication: Norepinephrine should generally not be given to patients with mesenteric or peripheral vascular thrombosis due to risk of increasing ischemia and extending infarction
• Exception clause: Administration may be necessary "as a life-saving procedure" in the opinion of the attending physician 2
• Specific warning: Gangrene has been reported when norepinephrine infusions were given in ankle veins, particularly in elderly patients or those with occlusive vascular disease 2

Clinical Decision Algorithm

1. Assess the Clinical Context

• If hypotension is life-threatening (MAP <65 mmHg with organ hypoperfusion): Norepinephrine is indicated despite gangrene presence
• If gangrene is from active mesenteric/peripheral thrombosis: This represents the highest risk scenario, but norepinephrine may still be justified if truly life-saving 2

2. Optimize Administration Route

• Use central venous access when possible - avoid peripheral administration in patients with pre-existing vascular compromise
• Never use lower extremity veins, especially in elderly patients or those with peripheral vascular disease 2
• Prefer antecubital or other large upper extremity veins if central access unavailable 2

3. Implement Risk Mitigation Strategies

• Start at lowest effective dose and titrate to MAP target of 65 mmHg 1
• Add vasopressin early (up to 0.03 U/min) to reduce norepinephrine requirements rather than escalating norepinephrine to high doses 1, 3
• Monitor infusion site continuously - never leave patient unattended 2
• Check blood pressure every 2 minutes initially, then every 5 minutes 2

4. Monitor for Progression

• Watch for blanching along vein course, which may indicate vasa vasorum constriction 2
• Consider changing infusion sites if blanching occurs 2
• Monitor for worsening peripheral ischemia in existing gangrenous areas

Evidence on Complications

While norepinephrine-induced peripheral ischemia and gangrene are documented complications 4, 5, 6, these typically occur in the context of:

• High-dose or prolonged therapy
• Sepsis with DIC
• Pre-existing peripheral vascular disease
• Lower extremity administration

The incidence appears relatively low when proper protocols are followed 7, 8.

Key Pitfalls to Avoid

1. Don't withhold norepinephrine in life-threatening hypotension - mortality from shock exceeds limb-loss risk
2. Don't use leg veins in patients with existing gangrene or vascular disease 2
3. Don't escalate norepinephrine indefinitely - add vasopressin at moderate NE doses rather than continuing to increase catecholamine exposure 3
4. Don't ignore extravasation signs - have phentolamine available for treatment 8

Bottom Line

The presence of gangrene is a relative, not absolute, contraindication to norepinephrine. When hypotension threatens life, norepinephrine should be initiated with appropriate precautions: central or upper extremity access, lowest effective doses, early addition of vasopressin, and intensive monitoring. The FDA explicitly acknowledges this may be necessary as a "life-saving procedure" 2.